Pancreatic Cancer Research

ResearcherAnhui Medical UniversityActive in the last 2 years

Pengwei Cao

ORCID-verified (high confidence, 0.95), identity_conf@1As of 8 November 2026

Matched on ORCID iD 0000-0001-8092-6820; OpenAlex author ID A5100830858. Sources: OpenAlex.

Their work

Papers
3
Trials
0
Grants
0
Labs led
0
Collaborators
5
Papers, trials and grants by year

2022: 1 paper · 2023: none · 2024: none · 2025: 1 paper · 2026: 1 paper

Papers 3

  1. Targeting HAS2 to enhance anti-tumor immunity in pancreatic cancer via PD-L1 regulation. Co-author DOI 10.1038/s42003-026-10009-1↗
  2. Cancer-Associated Fibroblast-Centric Risk Model Predicts Immunotherapy Resistance in Pancreatic Cancer and Reveals PLOD2 as a Key Stromal Therapeutic Target. Co-author DOI 10.31083/fbl46316↗
  3. Prognostic Value of Drug Targets Predicted Using Deep Bioinformatic Analysis of m6A-Associated lncRNA-Based Pancreatic Cancer Model Characteristics and Its Tum… Co-author DOI 10.3389/fgene.2022.853471↗

Closest collaborators

The 5 strongest of 5 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Daoxiang Zhang · 2 shared papers, 2025–2026 · strength 0.46
  2. Mengjie Lv · 2 shared papers, 2025–2026 · strength 0.46
  3. Fubao Liu · 2 shared papers, 2022–2025 · strength 0.44
  4. Chuifang Kong · 1 shared paper, 2026 · strength 0.23
  5. Lei Liu · 1 shared paper, 2022 · strength 0.20

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.